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Abstract: Prevalence of metabolic syndrome is increasing in the pediatric population. 
Considering the different existing criteria to define metabolic syndrome, the use of the 
International Diabetes Federation (IDF) criteria has been suggested in children. 
Docosahexaenoic acid (DHA) has been associated with beneficial effects on health. The 
evidence about the relationship of DHA status in blood and components of the metabolic 
syndrome is unclear. This review discusses the possible association between DHA content 
in plasma and erythrocytes and components of the metabolic syndrome included in the IDF 
criteria (obesity, alteration of glucose metabolism, blood lipid profile, and blood pressure) 
and non-alcoholic fatty liver disease in obese children. The current evidence is inconsistent 
and no definitive conclusion can be drawn in the pediatric population. Well-designed 
longitudinal and powered trials need to clarify the possible association between blood 
DHA status and metabolic syndrome. 
Keywords: metabolic syndrome; obesity; DHA; n-3 LCPUFA; glucose metabolism; lipid 
profile; blood pressure; NAFLD 
 
OPEN ACCESS




Childhood obesity is one of the most pressing public health issues [1] and a major risk for adult 
obesity and related comorbidities [2], which may already develop during pediatric age, such as insulin 
resistance, non-alcoholic fatty liver disease (NAFLD), type-2 diabetes mellitus (T2DM), dyslipidemia, 
hypertension, metabolic syndrome (MS), obstructive sleep apnea, joint problems, gallstones, and 
psychosocial problems [3]. 
There has been a marked increase in the prevalence of both obesity and metabolic syndrome in 
children over the past decades [4]. Metabolic syndrome is defined as a cluster of cardiovascular and 
type-2 diabetes risk factors, as hypertension, altered glucose metabolism, dyslipidemia, and abdominal 
obesity [5]. More than 40 definitions have been proposed to define metabolic syndrome and none of 
these is “universally accepted” [6]. However, some common features include the assessment of obesity 
(usually through body mass index (BMI) or waist circumference), the measurement of blood pressure 
and blood lipids (usually triglycerides (TG), high-density lipoprotein (HDL) cholesterol or low-density 
lipoprotein (LDL) cholesterol), and evaluation of risk factors associated with diabetes (fasting glucose, 
glucose tolerance and insulin resistance) [6]. 
Among different criteria to define metabolic syndrome in children, International Diabetes 
Federation (IDF), National Cholesterol Education Program’s Adult Treatment Panel III (ATP), and 
World Health Organization (WHO) criteria (with or without modification) are the most used [7]. 
Although there is no agreement on what criteria to use, recently the use of IDF-based criteria has been 
suggested [7]. The IDF definition of metabolic syndrome [8] in childhood is different according to age 
(6 to <10, 10 to <16, and ≥16 years). Below the age of 10 years the metabolic syndrome is not 
diagnosed; from 10 to 16 years the diagnosis requires the presence of abdominal obesity (waist 
circumference greater than or equal to the 90th percentile) plus the presence of two or more of: blood 
level of triglycerides ≥150 mg/dL, level of HDL-cholesterol <40 mg/dL, systolic blood pressure ≥130 
or diastolic blood pressure ≥85 mmHg, and fasting plasma glucose ≥100 mg/dL or known T2DM.  
In adolescents aged ≥16 years the IDF adult criteria can be used [8]. 
The prevalence of metabolic syndrome in children is highly variable according to the criteria used. 
A systematic review of studies using one of the main three criteria (IDF, ATP III, WHO) to define  
MS [7], highlighted that the median prevalence of metabolic syndrome was 3.3% in the whole 
population of children while it was 11.9% and 29.2% in overweight and obese children, respectively. 
Moreover, the median metabolic syndrome prevalence was higher in older (5.6%) than younger 
children (2.9%) and was higher in boys (5.2%) than girls (3.1%) [7]. Similar results were published in 
National Health and Examination Survey (NHANES) report [9] showing a metabolic syndrome 
prevalence in adolescents of 7.9% in boys compared to 6.7% in girls. Moreover, the prevalence of 
metabolic syndrome tends to be higher in pubertal than prepubertal children [6]. 
Finally, the link between metabolic syndrome and NAFLD should be evaluated. Indeed, in parallel 
to the rising epidemic of metabolic syndrome, also the prevalence of NAFLD has increased [10]. 
NAFLD is also often associated with clinical and biochemical features of metabolic syndrome [11] in 
children [12]. Although NAFLD might be considered the liver manifestation of the metabolic 
syndrome, this concept may be outdated [11]. A vicious cycle between NAFLD and metabolic 
syndrome could exist in pediatric age [13]. A recent review suggested that NAFLD is a determinant for 
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the onset of the metabolic syndrome and, therefore, a precursor [11]. Therefore, although to date 
NAFLD is not a component of the diagnostic criteria for metabolic syndrome its importance needs to 
be stressed [11,14]. 
2. Docosahexaenoic Acid: Metabolism and Properties 
Long chain n-3 polyunsaturated fatty acids (n-3 LCPUFAs) are long chain fatty acids (20 carbons or 
more), with the first double bond located after the third carbon from the methyl end [15]. Together 
with eicosapentaenoic acid (C20:5 (n-3), EPA) and docosapentaenoic acid (C22:5 (n-3), DPA), 
docosahexaenoic acid (C22:6 (n-3), DHA) is a main n-3 LCPUFAs in food sources [16]. Alfa-linolenic 
acid (C18:3 (n-3), ALA), an essential dietary fatty acid that cannot be synthesized in humans, is the 
precursor of all n-3 LCPUFAs [4]. Humans can convert ALA to EPA and DHA, but, since conversion 
efficiency is low, an adequate dietary intake is required [16]. 
Significant amounts of EPA and DHA characterize fish and derivative fish oil, especially salmon, 
tuna, mackerel, anchovy, and sardines, while ALA can be found in vegetable oils [4]. Moreover, DHA 
is found in human milk and it is necessary for optimal development of the brain and the retina of  
the infant [16]. However, DHA content in human milk varies substantially depending on the  
maternal intake of DHA, genetics, and other environmental factors [17], such as maternal smoking 
during pregnancy [18]. 
EPA and DHA intake through the diet increases the n-3 LCPUFA content of phospholipids, the 
main component of the cell membrane, also reducing arachidonic acid (AA) levels [15]. Fatty acids in 
erythrocyte are considered as the most reliable markers of habitual dietary intake of n-3 LCPUFAs, 
reflecting the intake over several months [19]. Fatty acids in plasma phospholipids reflect the intake 
over a relatively short period [19]. However, plasma phospholipids may reflect the fatty acids 
composition of erythrocyte lipids [20] and, in turn, erythrocyte fatty acids composition may reflect the 
fatty acids (especially PUFAs) composition of muscle membrane phospholipids [21]. 
n-3 LCPUFAs are associated with health benefits. EPA and DHA are essential for optimal fetal 
development and healthy aging [22], constitute phospholipids of most biological membranes with a 
relevant role in structure and function [16], have anti-inflammatory properties and modulate viscosity 
of cell membranes [22], and contribute to membrane fluidity, which can influence the function of 
membrane receptors [16]. Moreover, EPA and DHA are the precursors of numerous metabolites that 
function as lipid mediators with a plausible beneficial role in the prevention or treatment of several 
diseases [22]. Series D resolvins and protectins, two active metabolites derived from DHA, may 
modulate the inflammatory response by decreasing cytokine production and promoting the resolution 
of inflammation [23]. These metabolites could have a potential and important role in metabolic 
syndrome since a low-grade inflammation characterizes this condition [24]. It has been suggested that 
reducing the ratio of n-6/n-3 PUFA in diet (currently estimated about 10:1 in the Western diet), the risk 
factors of metabolic syndrome could be reduced [25]. However, the evidence about the relationship of 
n-3 PUFAs and components of the metabolic syndrome is inconsistent [26]. 
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Topic of Review 
This paper reviews the literature published in the last decade and discusses the relationships of 
blood DHA with each component of IDF criteria for metabolic syndrome (obesity, alteration of 
glucose metabolism, blood lipid profile and blood pressure) and NAFLD in obese children. 
3. Childhood Obesity: Relationship between DHA Content in Plasma and in Erythrocytes and 
Metabolic Syndrome Criteria and NAFLD 
3.1. Obesity 
Abdominal obesity, rather than obesity, can predict the presence of insulin resistance and related 
metabolic syndrome [27]. A systematic review and meta-analysis [28], including a total of 21 studies 
(11 conducted in childhood) for a total of 1575 participants, was performed in order to evaluate 
LCPUFA status in blood in overweight/obese subjects. Compared with healthy controls, overweight/ 
obese subjects showed lower DHA levels in total plasma lipids but no difference was found in plasma 
phospholipid and plasma cholesteryl ester fraction, suggesting that DHA deficiency might be not 
systemic [28]. 
Only a few studies have been conducted considering DHA status in blood among the obese 
pediatric population [29–36]. A case-control study on 67 normolipidemic obese children, aged  
8–12 years, and 67 age- and sex-matched normal-weight children, observed that obese children 
showed significantly lower levels of DHA/ALA ratio in total plasma fatty acids compared to  
normal-weight controls [29]. Moreover obese children in the highest quartile of BMI z-score showed 
lower levels of DHA, DHA/AA, and DHA/ALA ratios than normal-weight children, despite a higher 
dietary PUFAs intake, suggesting a metabolic dysfunction in the synthetic pathway of the n-3 series in 
severely obese children [29]. Saito et al. [30] assessed the analysis of fatty acid composition of plasma 
phospholipids in 32 obese children and found an inverse association (almost statistically significant) of 
DHA content with BMI. Similarly, a study found that 60 overweight adolescents had lower total n-3 
PUFA and DHA concentrations in plasma phospholipids, compared to normal-weight controls [31]. 
Another study conducted on adolescents, showed that obese girls, but not boys, had lower 
concentrations of n-3 PUFAs, including DHA in plasma phospholipids compared to normal-weight 
controls, and that DHA was inversely associated with all fat depots, measured by magnetic resonance 
imaging, except visceral adipose tissue, both in girls and in boys [32]. Furthermore, in another study, 
obese children showed after one year of nutritional-behavioral intervention a decreased BMI z-score of 
12.3% and increased plasma levels of DHA and DHA⁄AA ratio, compared to baseline, with a 
consequent disappearance of the difference for DHA⁄AA ratio between obese children and  
normal-weight controls [33]. It should be interestingly noted that in this study, whereas the plasma 
PUFA increased after one year, the dietary PUFA intake decreased [33]. However, further studies are 
needed to better clarify the role of dietary change on specific plasma fatty acid in obese children. On 
the contrary, a study performed on obese prepubertal children with metabolic syndrome showed higher 
levels of DHA in total plasma lipids, compared to normal-weight controls while no difference was 
observed in plasma phospholipid and plasma cholesteryl ester fraction [34]. Another study found no 
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difference in total plasma lipid levels of DHA between obese children and normal-weight  
controls [35]. 
Moreover, in a recent study, 33% of obese children showed an n-3 index (calculated by adding 
EPA% and DHA% (weight/weight) values) <4.0 (associated to high risk of cardiovascular disease) in 
erythrocytes compared to 17% of non-obese children, suggesting that obese children may have an 
altered erythrocyte fatty acid composition [36]. 
As a whole, several discussed studies found blood DHA may be lower in obese children and 
negatively associated with the degree of obesity, but further studies are needed to better understand the 
relationship between DHA status and obesity. 
3.2. Glucose Metabolism Alterations 
An important key factor in the pathogenesis of metabolic syndrome is insulin resistance [37], a 
whole-body decrease in the ability of insulin to stimulate the use of glucose by muscles and adipose 
tissue and to suppress glucose production in the liver [38]. Prevalence of insulin resistance has 
increased significantly in children in the last three decades [39]. Indeed, the analysis of the US 
NHANES 1999–2002, involving 1802 adolescents without diabetes, has shown that insulin resistance 
prevalence was 52% among obese children [40]. A marked increase of the prevalence of pre-diabetic 
stages’ conditions and type 2 diabetes mellitus among obese children and adolescents has also been 
observed [39]. 
Low levels of LCPUFAs, especially DHA, and a high n-6/n-3 LCPUFA ratio in skeletal muscle 
membrane phospholipids have been associated with insulin resistance in adults [41]. Moreover, 
membrane flexibility, determined by the polyunsaturated fatty acid/saturated fatty acid (PUFA/SFA) 
ratio, could impact on the effectiveness of glucose transport by insulin-independent glucose 
transporters (GLUTs) and the insulin-dependent GLUT4 [42]. 
Literature concerning blood DHA status in the pediatric obese population is scanty [30–33,43,44]. 
In obese children, DHA content in plasma phospholipids was not associated with parameters of 
glucose metabolism as fasting glucose, fasting insulin, and homeostasis model assessment-insulin 
resistance (HOMA-IR) [30]. The lack of association between plasma DHA levels and HOMA-IR was 
confirmed in other different studies [31,33]. On the contrary, a study found that DHA in plasma 
phospholipids was inversely associated with serum insulin and HOMA β-cell function [32] and other 
studies conducted on obese children showed that HOMA-IR was negatively associated with DHA in 
plasma phospholipids [43,44]. 
On the whole, the evidence from existing literature is not conclusive about the association between 
DHA status in blood and glucose metabolism alterations in obese children. However, it should be 
pointed out that breastfeeding, as the best feeding practice in early life, could have a protective role on 
glucose metabolism derangements [45,46], possibly also involving DHA in breast milk [18,45]. 
Indeed, fatty acids composition of breast milk, including DHA, may increase LCPUFAs in skeletal 
muscle membranes protecting against insulin resistance, β-cell failure, and type-2 diabetes [18,45]. 
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3.3. Abnormal Blood Lipid Profile 
The alterations of blood lipid profile associated with metabolic syndrome are usually characterized 
by increased triglycerides, very-low-density lipoproteins (VLDLs), small dense LDL particles, and 
reduced HDL cholesterol levels [47,48]. Visceral obesity and insulin resistance could be key factors 
involved in the promotion of atherogenic dyslipidemia by increasing the synthesis of TG-rich VLDLs 
in the liver [4]. 
In adults, increased plasma levels of EPA and DHA might be inversely associated with the risk of 
the progression of coronary atherosclerosis, sudden cardiac death, and coronary heart disease, clinical 
conditions related to risk factors for cardiovascular disease, including dyslipidemia [49]. 
The possible relationships of DHA with blood lipid profile have been poorly investigated in the 
pediatric population [30,31,33]. A study performed on 32 obese children showed that plasma 
phospholipids’ DHA content was negatively associated with VLDL-triglyceride, a major factor 
involved in the development of metabolic syndrome [30]. A cross-sectional study did not find any 
associations of DHA in both plasma phospholipids and cholesteryl esters with parameters of blood 
lipid profile in overweight adolescents, while the PUFA/SFA and linoleic acid levels in plasma 
phospholipids were positively associated with HDL cholesterol [31]. Another study, analyzing  
total plasma fatty acids on 57 normolipidemic obese children, concluded that after one year of  
nutritional-behavioral intervention changes in plasma DHA and DHA/AA ratio (both increased) were 
inversely associated with changes in plasma total TGs [33]. 
In conclusion, association between plasma DHA levels and blood lipid profile alterations in 
pediatric obese population is inconsistent. 
3.4. Blood Pressure Alterations 
The prevalence rates of hypertension and obesity are increasing worldwide in children [50]. The 
blood pressure lowering effect of DHA, observed in adults, could be mediated by the adenosine 
triphosphate (ATP) release from the endothelium, which increases vasodilation by stimulating the 
release of nitric oxide, and by the decrease in noradrenaline levels [51]. 
To our knowledge, only one study evaluated the association between DHA status in blood and 
blood pressure in obese children. This study, analyzing plasma fatty acid composition in 60 overweight 
adolescents found that DHA status was not associated with systolic blood pressure [31]. 
Regarding breastfeeding, a systematic review stated that breastfeeding has a small protective effect 
against high systolic blood pressure, although residual confounders had to be eliminated [45]. One of 
the plausible mechanisms that has been suggested to explain this protective effect is represented by the 
presence of LCPUFAs, including DHA, which are important structural components of the vascular 
endothelium [45]. In a multicenter, randomized, controlled trial, children fed with a formula 
supplemented with LCPUFAs (mainly DHA and EPA) showed at age 6 years lower blood pressure 
than children fed with a formula without LCPUFAs [52]. 
In conclusion, while in adults an association of DHA status with blood pressure has been observed, 
in obese children the literature is limited and further longitudinal studies would be desirable. 
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3.5. NAFLD (Non-Alcoholic Fatty Liver Disease) 
In children of industrialized countries, NAFLD is the most common chronic liver disease, reaching 
a prevalence up to 80% in obese or overweight children [53]. NAFLD includes different diseases 
ranging from “simple” liver steatosis, with pathological accumulation of fat in excess of 5% of liver 
weight, non-alcoholic steatohepatitis (NASH), with different degree of inflammation and fibrosis, to 
end-stage liver disease with cirrhosis and hepatocellular carcinoma [54]. 
Obese adults with NAFLD showed lower levels of n-3 LCPUFAs, EPA, DHA, and a higher n-6/n-3 
ratio in liver than controls [55]. Lower n-3 LCPUFA levels in liver have also been associated with 
lower levels in erythrocyte phospholipids [56]. The low n-3 LCPUFA levels in liver, by promoting  
the synthesis of fatty acids and triglycerides with parallel imbalance in the oxidation of fatty acids  
and export of triglycerides from the liver, could determine fat accumulation and promote liver  
steatosis [55,57]. To our knowledge there are no studies investigating the association between fatty 
acids composition of liver phospholipids, and especially liver levels of DHA, and NAFLD in obese 
children. Only one study showed that in obese children with single-nucleotide polymorphism (SNP), 
276G>T at adiponectin gene, the increased liver echogenicity could be associated with higher levels of 
n-6 PUFA in plasma phospholipids (unpublished results, presented at 44th ESPGHAN Annual 
Meeting, Sorrento) [58]. However, some trials evaluated the effect of DHA supplementation on 
pediatric NAFLD [59,60]. A reduced liver hyperechogenicity was observed in children with NAFLD 
after DHA supplementation for 6, 12, 18, and 24 months [59]. After 18 months of DHA treatment an 
improvement of histo-pathological parameters (NAFLD activity score, ballooning, and steatosis) has 
been also observed [60]. 
Only one study has evaluated the association between breastfeeding and NAFLD in children. This 
retrospective study suggested that breastfeeding might be protective against NASH and liver fibrosis, 
suggesting a long-lasting effect of breast milk DHA [61]. The authors speculated that DHA,  
supplied by breast milk, could be protective, acting as a peroxisome proliferator-activated receptors  
(PPAR)-agonist,  a transcription factor involved in protection against fibrosis [61,62]. 
In conclusion, further studies are needed to evaluate the existence of a relationship between DHA 
status in blood and NAFLD in children and to confirm the protective role of DHA in breast milk 
against NAFLD progression. 
4. Discussion and Conclusion 
The metabolic syndrome, considered in the past as an adulthood disorder, also affects children with 
increasing prevalence [4,5]. 
DHA has been associated with beneficial effects on health and in treatment of several diseases [22], 
such as cardiovascular disease, cancer, inflammatory, thrombotic and autoimmune disease, coronary 
heart disease, hypertension, and type-2 diabetes, in adults [16]. The reduction of dietary n-6/n-3 PUFA 
ratio could reduce risk factors associated with metabolic syndrome [25,63]. 
Table 1 summarizes the observed relationship between DHA content in plasma and erythrocytes 
and components of IDF criteria for metabolic syndrome in obese children. The current evidence  
is inconsistent and no definitive conclusion can be drawn in the pediatric population. Further  
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well-designed studies are needed to evaluate a possible role of DHA supplementation as a prevention 
strategy of obesity-related comorbidities in childhood. 
Table 1. DHA status in blood and components of IDF criteria for metabolic syndrome in 
obese children. 
Metabolic Syndrome Components [Ref] Blood DHA Status 
Obesity [29–36] 
DHA content is lower in obese children and 
negatively associated with the degree of 
obesity, except for two studies [34,35] 
Glucose metabolism alterations [30–33,43,44] Inconsistent results 
Abnormal blood lipid profile [30,31,33] Inconsistent results 
Blood pressure alterations [31] None association with systolic blood pressure 
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